12:00 AM
 | 
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Nepafenac regulatory update

Novartis disclosed in its 4Q11 earnings that it submitted an NDA to FDA for once-daily Nevanac nepafenac to treat pain and inflammation following cataract...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >